Corcept Therapeutics Incorporated (CORT)

Market Cap	7.62B
Revenue (ttm)	685.45M
Net Income (ttm)	132.51M
Shares Out	106.04M
EPS (ttm)	1.14
PE Ratio	62.89
Forward PE	50.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	789,661
Open	69.88
Previous Close	n/a
Day's Range	69.60 - 72.55
52-Week Range	28.04 - 117.33
Beta	0.18
Analysts	Strong Buy
Price Target	142.00 (+97.63%)
Earnings Date	Jul 28, 2025

About CORT

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 500
• Stock Exchange: NASDAQ
• Ticker Symbol: CORT
• Website: https://www.corcept.com

Financial Performance

In 2024, Corcept Therapeutics's revenue was $675.04 million, an increase of 39.94% compared to the previous year's $482.38 million. Earnings were $139.73 million, an increase of 32.45%.

Analyst Forecast

According to 4 analysts, the average rating for CORT stock is "Strong Buy." The 12-month stock price forecast is $142.0, which is an increase of 97.63% from the latest price.

Price Target

$142.0

(97.63% upside)

Analyst Consensus: Strong Buy